{"id":"W4376613563","doi":"10.1016/j.esmoop.2023.101385","title":"196P Efficacy and safety of first-line (1L) ribociclib (RIB) + letrozole (LET) in patients (pts) with de novo metastatic disease and late recurrence from (neo)adjuvant therapy (tx) in MONALEESA (ML)-2","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Bristol-Myers Squibb; Samsung; Genentech; Daiichi-Sankyo; Eisai; Novartis Pharmaceuticals Corporation; Ascentage Pharma; Argenx; Syndax Pharmaceuticals; Mirati Therapeutics; Les Laboratories Pierre Fabre; TG Therapeutics; AstraZeneca; Novocure; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Amgen; Pfizer; G1 Therapeutics; Ipsen Biopharmaceuticals; Celgene; Carrick Therapeutics; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Letrozole; Adjuvant; Gastroenterology; Progression-free survival; Surgery; Chemotherapy; Cancer; Breast cancer; Oncology; Aromatase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000290248,0.0002232645,0.0005431257,0.0001434959,0.00005049654,0.00002303912,0.0001957066,0.00003296199,0.00008335834],"category_scores_gemma":[0.0001103824,0.0001762547,0.00002507345,0.0004532556,0.000162618,0.0002302362,0.0001712649,0.0002076541,0.000006491531],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001213739,"about_ca_system_score_gemma":0.0001184967,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001828255,"about_ca_topic_score_gemma":0.001502362,"domain_scores_codex":[0.998528,0.00009649734,0.0003748202,0.0004283685,0.0002560823,0.0003162517],"domain_scores_gemma":[0.9990242,0.0002664042,0.0001420341,0.0003243874,0.00005921795,0.00018376],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01384138,0.0005434913,0.904622,0.00009566041,0.0001445153,0.0001746172,0.002071144,0.0005693266,0.0001085082,0.00002718735,0.0000157245,0.07778643],"study_design_scores_gemma":[0.02023916,0.0004691244,0.9749519,0.0008324772,0.00004844478,0.000003235158,0.0001090721,0.0006591027,0.00023278,0.0007004515,0.001561618,0.0001926936],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963526,0.001016248,0.0000720266,0.001010366,0.00003143741,0.001258149,0.0001873997,0.00002216628,0.00004961351],"genre_scores_gemma":[0.9968811,0.001185584,0.001246721,0.0002502936,0.0000185376,0.00009477494,0.0001779766,0.00003671338,0.0001083462],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07759374,"threshold_uncertainty_score":0.7187459,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02612377177042233,"score_gpt":0.3038011649631449,"score_spread":0.2776773931927226,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}